CEL-SCI Co. (NYSE:CVM) CEO Buys $41,700.00 in Stock

CEL-SCI Co. (NYSE:CVM) CEO Geert R. Kersten acquired 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 8th. The shares were purchased at an average price of $1.39 per share, with a total value of $41,700.00. Following the completion of the transaction, the chief executive officer now owns 1,195,309 shares of the company’s stock, valued at approximately $1,661,479.51. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

CEL-SCI Trading Up 3.6 %

Shares of CVM stock traded up $0.05 during trading hours on Thursday, hitting $1.44. The company had a trading volume of 282,816 shares, compared to its average volume of 330,349. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.26 and a quick ratio of 0.78. The stock has a market capitalization of $77.73 million, a PE ratio of -2.03 and a beta of 1.23. The company’s fifty day moving average is $1.80 and its 200 day moving average is $2.21. CEL-SCI Co. has a fifty-two week low of $1.04 and a fifty-two week high of $3.23.

CEL-SCI (NYSE:CVM) last released its quarterly earnings results on Wednesday, February 14th. The company reported ($0.14) EPS for the quarter. Research analysts expect that CEL-SCI Co. will post -0.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, StockNews.com cut CEL-SCI from a “hold” rating to a “sell” rating in a research note on Friday, March 15th.

Institutional Trading of CEL-SCI

Hedge funds have recently made changes to their positions in the business. Chilton Capital Management LLC grew its stake in CEL-SCI by 297.4% during the 1st quarter. Chilton Capital Management LLC now owns 16,302 shares of the company’s stock worth $31,000 after purchasing an additional 12,200 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in CEL-SCI by 2,011.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 16,198 shares of the company’s stock worth $44,000 after acquiring an additional 15,431 shares in the last quarter. Forthright Family Wealth Advisory LLC acquired a new position in shares of CEL-SCI during the fourth quarter worth $45,000. Sheets Smith Wealth Management acquired a new stake in CEL-SCI in the fourth quarter valued at $54,000. Finally, Black Diamond Financial LLC lifted its holdings in CEL-SCI by 20.5% during the 3rd quarter. Black Diamond Financial LLC now owns 53,000 shares of the company’s stock worth $66,000 after buying an additional 9,000 shares during the last quarter. Institutional investors and hedge funds own 12.08% of the company’s stock.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.